Top

Clinical and Translational Oncology

Published in:

01-01-2013 | Research Article

CD44⁺/CD24⁻ breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties

Authors: Hongmei Sun, Jun Jia, Xiaoli Wang, Bo Ma, Lijun Di, Guohong Song, Jun Ren

Published in: Clinical and Translational Oncology | Issue 1/2013

Abstract

Background

Recent studies suggest that the relationship between cancer stem cells (CSCs) and the vascular niche may be bidirectional; the niche can support the growth and renewal of CSCs, and CSCs may contribute to the maintenance of the niche. There is little knowledge concerning the role of breast cancer stem cells in promoting tumor angiogenesis.

Aim

For human breast cancers, CSCs have been shown to be associated with a CD44⁺/CD24⁻ phenotype. We investigated the potential activities of CD44⁺/CD24⁻ breast cancer stem cells in promoting tumor angiogenesis.

Methods

The expression of pro-angiogenic genes was determined by quantitative real-time RT-PCR. Endothelial cell migration assays were employed to evaluate effects of conditioned media from CD44⁺/CD24⁻ on human umbilical vein endothelial cells. A chorioallantoic membrane (CAM) assay was used to study the potential of CD44⁺/CD24⁻ cells to promote angiogenesis.

Results

In our study, CD44⁺/CD24⁻ cells expressed elevated levels of pro-angiogenic factors compared with CD44⁺/CD24⁺ cells. CD44⁺/CD24⁻ cell-conditioned media significantly increased endothelial cell migration. Breast cancer cell lines enriched with CD44⁺/CD24⁻ cells were more pro-angiogenic in the CAM assay than those lacking a CD44⁺/CD24⁻ subpopulation. CD44⁺/CD24⁻ cells sorted from MCF-7 cell lines were more pro-angiogenic in a CAM assay than CD44⁺/CD24⁺ cells. Furthermore, the VEGF concentration was significantly higher in CD44⁺/CD24⁻ cell-conditioned media than in CD44⁺/CD24⁺ cell-conditioned media. The pro-angiogenic effect of CD44⁺/CD24⁻ cells on endothelial cells was abolished by bevacizumab.

Conclusion

Our findings demonstrate that CD44⁺/CD24⁻ breast cancer stem cells have substantial pro-angiogenic potential and activity. This provides new insights to explore in the development of targeted therapies.

Calabrese C, Poppleton H, Kocak M et al (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11(1):69–82PubMedCrossRef

Beck B, Driessens G, Goossens S et al (2011) A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 478(7369):399–403PubMedCrossRef

Shen R, Ye Y, Chen L et al (2008) Precancerous stem cells can serve as tumor vasculogenic progenitors. PloS One 3(2):e1652PubMedCrossRef

Wang R, Chadalavada K, Wilshire J et al (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468(7325):829–833PubMedCrossRef

Sneddon JB, Werb Z (2007) Location, location, location: the cancer stem cell niche. Cell Stem Cell 1(6):607–611PubMedCrossRef

Bao S, Wu Q, Sathornsumetee S et al (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66(16):7843–7848PubMedCrossRef

Al-Hajj M, Wicha MS, Benito-Hernandez A et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983–3988PubMedCrossRef

Gong JF, Yuan YH, Song GH et al (2008) Pilot study on the correlation between high incidence of CD44+/CD24⁻/low/ABCG2-cells and poor prognosis in breast cancer. Beijing Da Xue Xue Bao 40(5):465–470

Abraham BK, Fritz P, McClellan M et al (2005) Prevalence of CD44+/CD24⁻/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 11(3):1154–1159PubMed

10.

Liu R, Wang X, Chen GY et al (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. New Engl J Med 356(3):217–226PubMedCrossRef

11.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4):402–408

12.

Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nature Rev 5(4):275–284CrossRef

13.

Okabe M, Tsukahara Y, Tanaka M et al (2009) Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver. Development 136(11):1951–1960

14.

Ginestier C, Hur MH, Charafe-Jauffret E et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567PubMedCrossRef

15.

Croker AK, Goodale D, Chu J et al (2009) High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 13(8B):2236–2252PubMedCrossRef

16.

Charafe-Jauffret E, Ginestier C, Monville F et al (2006) Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25(15):2273–2284PubMedCrossRef

17.

Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874PubMedCrossRef

18.

Ailles LE, Weissman IL (2007) Cancer stem cells in solid tumors. Curr Opin Biotechnol 18(5):460–466PubMedCrossRef

19.

Ponti D, Costa A, Zaffaroni N et al (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65(13):5506–5511PubMedCrossRef

20.

Zhang Y, Toy KA, Kleer CG (2012) Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition. Mod Pathol 25(2):178–184PubMed

21.

Ratajczak M, Tarnowski M, Staniszewska M et al (2010) Mechanisms of cancer metastasis: involvement of cancer stem cells? Minerva Med 101(3):179–191PubMed

22.

Arima Y, Hayashi N, Hayashi H et al (2012) Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer. Int J Cancer 130(11):2568–2579 PubMedCrossRef

23.

Idowu MO, Kmieciak M, Dumur C et al (2012) CD44(+)/CD24(−/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 43(3):364–373PubMedCrossRef

24.

Sheridan C, Kishimoto H, Fuchs RK et al (2006) CD44+/CD24− breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8(5):R59PubMedCrossRef

25.

Saarinen NM, Abrahamsson A, Dabrosin C (2010) Estrogen-induced angiogenic factors derived from stromal and cancer cells are differently regulated by enterolactone and genistein in human breast cancer in vivo. Int J Cancer 127(3):737–745PubMedCrossRef

26.

Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev 9(4):239–252CrossRef

27.

Ambasta RK, Sharma A, Kumar P (2011) Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy. Vasc Cell 3(1):26PubMedCrossRef

28.

Liekens S, Schols D, Hatse S (2011) CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr Pharm Des 16(35):3903–3920CrossRef

29.

Ehtesham M, Mapara KY, Stevenson CB et al (2009) CXCR4 mediates the proliferation of glioblastoma progenitor cells. Cancer Lett 274(2):305–312PubMedCrossRef

30.

Sakariassen PO, Prestegarden L, Wang J et al (2006) Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci USA 103(44):16466–16471PubMedCrossRef

31.

Jeyapalan Z, Deng Z, Shatseva T et al (2011) Expression of CD44 3′-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis. Nucleic Acids Res 39(8):3026–3041PubMedCrossRef

32.

Bretz N, Noske A, Keller S et al (2011) CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion. Clin Exp Metastasis 29(1):27–38

33.

Schabath H, Runz S, Joumaa S et al (2006) CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 119(Pt 2):314–325PubMedCrossRef

34.

Kerbel RS (2008) Tumor angiogenesis. New Engl J Med 358(19):2039–2049PubMedCrossRef

35.

Kim KJ, Li B, Winer J et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423):841–844PubMedCrossRef

36.

Relf M, LeJeune S, Scott PA et al (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57(5):963–969PubMed

37.

Hanrahan V, Currie MJ, Gunningham SP et al (2003) The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 200(2):183–194PubMedCrossRef

38.

Viacava P, Naccarato AG, Bocci G et al (2004) Angiogenesis and VEGF expression in pre-invasive lesions of the human breast. J Pathol 204(2):140–146PubMedCrossRef

39.

Bergers G, Javaherian K, Lo KM et al (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284(5415):808–812

40.

Hamilton EP, Blackwell KL (2011) Safety of bevacizumab in patients with metastatic breast cancer. Oncology 80(5–6):314–325PubMedCrossRef

41.

Besancon R, Valsesia-Wittmann S, Puisieux A et al (2009) Cancer stem cells: the emerging challenge of drug targeting. Curr Med Chem 16(4):394–416PubMedCrossRef

Title: CD44+/CD24− breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties
Authors: Hongmei Sun
Jun Jia
Xiaoli Wang
Bo Ma
Lijun Di
Guohong Song
Jun Ren
Publication date: 01-01-2013
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 1/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0891-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Aim

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2013

Analysis of economic evaluations of pharmacological cancer treatments in Spain between 1990 and 2010

SEOM recommendations on the structure and operation of hereditary cancer genetic counseling units (HCGCUs)

Tumor bed segmentation: first step for partial breast irradiation

Retreatment with radiotherapy for symptomatic bone, brain or visceral metastases

Accuracy and axilla sparing potentials of sentinel lymph node biopsy with methylene blue alone performed before versus after neoadjuvant chemotherapy in breast cancer: a single institution experience

Next-generation sequencing reveals the secrets of the chronic lymphocytic leukemia genome

Keynote webinar | Spotlight on antibody–drug conjugates in cancer